Influence of alpha-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'-5'oligoadenylate synthetase activity

Cancer Immunol Immunother. 1987;24(3):190-6. doi: 10.1007/BF00205628.

Abstract

The influence of natural alpha-interferon (alpha-IFN) therapy (3 X 10(6) units i.m. daily) on blood lymphoid cells was studied in 20 patients with gynecological neoplasias (7 patients with condylomata accuminata and 13 patients with ovarian carcinoma). There was a statistically significant increase in the intracellular levels of 2'-5'oligoadenylate synthetase 1 day after the first injection of IFN and with few exceptions this activity remained increased during 3 months of treatment. In most of the patients, the capacity of blood lymphoid cells to produce IgA, IgG, and IgM following stimulation with pokeweed mitogen was decreased 1 day after the first injection of IFN and with few exceptions it remained low during 6 months of IFN therapy. In most patients there was a decrease in the capacity of lymphoid cells to act as stimulator or responder cells in a mixed lymphocyte culture during IFN therapy. The alpha-IFN therapy had no major influence on the response of lymphoid cells to mitogens. We conclude, that neither this nor our previous studies on the influence of IFN therapy on immunological functions have given support to the hypothesis that the antitumor action of IFN is mediated by the immune system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2',5'-Oligoadenylate Synthetase / metabolism*
  • Adult
  • Aged
  • Antibody Formation / drug effects*
  • Carcinoma / immunology
  • Carcinoma / therapy
  • Condylomata Acuminata / immunology
  • Condylomata Acuminata / therapy
  • Female
  • Humans
  • Interferon Type I / pharmacology
  • Interferon Type I / therapeutic use*
  • Lymphocyte Activation / drug effects
  • Lymphocyte Culture Test, Mixed
  • Middle Aged
  • Ovarian Neoplasms / immunology
  • Ovarian Neoplasms / therapy

Substances

  • Interferon Type I
  • 2',5'-Oligoadenylate Synthetase